Dual release of daptomycin and BMP-2 from a composite of β-TCP ceramic and ADA gelatin

BMC Biotechnol. 2024 Jun 3;24(1):38. doi: 10.1186/s12896-024-00863-4.

Abstract

Background: Antibiotic-containing carrier systems are one option that offers the advantage of releasing active ingredients over a longer period of time. In vitro sustained drug release from a carrier system consisting of microporous β-TCP ceramic and alginate has been reported in previous works. Alginate dialdehyde (ADA) gelatin gel showed both better mechanical properties when loaded into a β-TCP ceramic and higher biodegradability than pure alginate.

Methods: Dual release of daptomycin and BMP-2 was measured on days 1, 2, 3, 6, 9, 14, 21, and 28 by HPLC and ELISA. After release, the microbial efficacy of the daptomycin was verified and the biocompatibility of the composite was tested in cell culture.

Results: Daptomycin and the model compound FITC protein A (n = 30) were released from the composite over 28 days. A Daptomycin release above the minimum inhibitory concentration (MIC) by day 9 and a burst release of 71.7 ± 5.9% were observed in the loaded ceramics. Low concentrations of BMP-2 were released from the loaded ceramics over 28 days.

Keywords: ADA-gelatin gel; BMP-2; Bone infection; Daptomycin; Dual release; β-TCP scaffold.

MeSH terms

  • Animals
  • Anti-Bacterial Agents* / chemistry
  • Anti-Bacterial Agents* / pharmacology
  • Bone Morphogenetic Protein 2* / chemistry
  • Bone Morphogenetic Protein 2* / metabolism
  • Calcium Phosphates* / chemistry
  • Ceramics* / chemistry
  • Daptomycin* / chemistry
  • Daptomycin* / pharmacology
  • Drug Carriers / chemistry
  • Drug Liberation
  • Gelatin* / chemistry
  • Mice
  • Microbial Sensitivity Tests

Substances

  • Bone Morphogenetic Protein 2
  • Daptomycin
  • Gelatin
  • beta-tricalcium phosphate
  • Anti-Bacterial Agents
  • Calcium Phosphates
  • Drug Carriers